Publications by authors named "David Angulo"

Claim this Profile
A
A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis.
Oluwatosin Goje, Nkechi E Azie, David A Angulo, Ryan Sobel, Paul Nyirjesy

Am J Obstet Gynecol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need.
Yuliya Yasinskaya, Shukal Bala, Ursula Waack, Cheryl Dixon, Karen Higgins, David Angulo

Clin Infect Dis· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306.
Oluwatosin Goje, Ryan Sobel, Paul Nyirjesy, Steven R Goldstein, Mark Spitzer, David Angulo

J Womens Health (Larchmt)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections.
David A Angulo, Barbara Alexander, Riina Rautemaa-Richardson, Ana Alastruey-Izquierdo, Martin Hoenigl

J Fungi (Basel)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis.
Paul Nyirjesy, Jane R Schwebke, David A Angulo, Itzel A Harriott, Nkechi E Azie

Clin Infect Dis· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
Jane R Schwebke, Ryan Sobel, Janet K Gersten, Steven A Sussman, Samuel N Lederman, David A Angulo

Clin Infect Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.
Elizabeth O'Shaughnessy, Yuliya Yasinskaya, Cheryl Dixon, Karen Higgins, Jason Moore, David Angulo

Clin Infect Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of : A European Study.
Guillermo Quindós, Katherine Miranda-Cadena, Rosario San-Millán, Katyna Borroto-Esoda, Emilia Cantón, David Angulo

Front Cell Infect Microbiol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against .
Ahmed Gamal, Sherman Chu, Thomas S McCormick, Katyna Borroto-Esoda, David Angulo

Front Cell Infect Microbiol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Isolates from Women with Vulvovaginal Candidiasis.
Jack D Sobel, Katyna Borroto-Esoda, Nkechi Azie, David Angulo

Antimicrob Agents Chemother· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are We Ready for Bariatric Surgery in a Liver Transplant Program? A Meta-Analysis.
Víctor Lopez-Lopez, Juan José Ruiz-Manzanera, Dilmurodjon Eshmuminov, Kuno Lehmann, Marcel Schneider, David Ruiz de Angulo

Obes Surg· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis.
Nkechi Azie, David Angulo, Barbara Dehn, Jack D Sobel

Expert Opin Investig Drugs· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case report of Tourniquet ALPPS and simultaneous sleeve gastrectomy: A valuable association to achieve an adequate future liver remnant in obese patients.
Roberto Brusadin, Víctor López-López, David Ruiz de Angulo, Asunción López-Conesa, Álvaro Navarro-Barrios

Medicine (Baltimore)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Infections.
Mahmoud Ghannoum, Maiken Cavling Arendrup, Vishnu P Chaturvedi, Shawn R Lockhart, Thomas S McCormick, David Angulo

Antibiotics (Basel)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Vidmantas Petraitis, Ruta Petraitiene, Aspasia Katragkou, Bo Bo Win Maung, Ethan Naing, David Angulo

Antimicrob Agents Chemother· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model.
Annie Lee, Brendan Prideaux, Matthew Zimmerman, Claire Carter, Stephen Barat, David Angulo

Antimicrob Agents Chemother· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with Mutations.
Natalie S Nunnally, Kizee A Etienne, David Angulo, Shawn R Lockhart, Elizabeth L Berkow

Antimicrob Agents Chemother· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
Andrej Spec, John Pullman, George R Thompson, William G Powderly, Ellis H Tobin, David Angulo

J Antimicrob Chemother· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [C]SCY-078 in Albino and Pigmented Rats.
Stephen Wring, Katyna Borroto-Esoda, Eric Solon, David Angulo

Antimicrob Agents Chemother· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus.
Stephen Wring, Gail Murphy, George Atiee, Christy Corr, Michele Hyman, David Angulo

Clin Pharmacol Drug Dev· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions.
Stephen Wring, Gail Murphy, George Atiee, Christy Corr, Michele Hyman, David Angulo

J Clin Pharmacol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content.
Brandon M Kirsch, Laurie Burke, Jeremy Hobart, David Angulo, Patricia S Walker

J Drugs Dermatol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance.
Cristina Jiménez-Ortigosa, Winder B Perez, David Angulo, Katyna Borroto-Esoda, David S Perlin

Antimicrob Agents Chemother· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris.
Elizabeth L Berkow, David Angulo, Shawn R Lockhart

Antimicrob Agents Chemother· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.
Emily Larkin, Christopher Hager, Jyotsna Chandra, Pranab K Mukherjee, Mauricio Retuerto, David Angulo

Antimicrob Agents Chemother· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis